Harry Drummond
Family Medicine · Simi Valley, CANPI 1164416517
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 325 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,525 and has fallen 98.9% since, to $16 in 2025. Among family medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 325 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Boehringer Ingelheim$832
- AstraZeneca$823
- AbbVie$713
- Johnson & Johnson$295
- Lilly USA, LLC$261
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,187100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 60 | $1,037 |
| Boehringer Ingelheim | 45 | $832 |
| AstraZeneca | 45 | $823 |
| AbbVie(2 entities) | 35 | $713 |
| Johnson & Johnson | 16 | $295 |
| Lilly USA, LLC | 12 | $261 |
| Amgen | 10 | $225 |
| Bayer | 13 | $224 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $208 |
| Merck | 10 | $197 |
| GSK | 8 | $166 |
| Novartis | 7 | $151 |
| Sanofi-aventis U.S. LLC | 6 | $136 |
| Biohaven Pharmaceuticals, Inc. | 6 | $135 |
| Amarin Pharma, Inc. | 5 | $105 |
| Idorsia Pharmaceuticals US Inc | 5 | $99 |
| Lundbeck LLC | 4 | $69 |
| Gilead | 3 | $61 |
| Arbor Pharmaceuticals, Inc. | 3 | $50 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $50 |
| Kowa Pharmaceuticals America, Inc. | 3 | $47 |
| Eisai Inc. | 2 | $40 |
| Astellas Pharma US Inc | 2 | $37 |
| Pfizer | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Dynavax Technologies Corporation | 1 | $26 |
| Vertiflex, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Dermira, Inc. | 1 | $17 |
| Abbott | 1 | $17 |
| Apria Healthcare LLC | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
How this compares
$6,192 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 51 | $623 |
| Gabapentin | 25 | $286 |
| Levothyroxine Sodium | 27 | $273 |
| Losartan Potassium | 30 | $223 |
| Amlodipine Besylate | 22 | $173 |
| Metformin Hcl | 21 | $133 |
| Rosuvastatin Calcium | 11 | $128 |
| Metoprolol Succinate | 11 | $115 |
| Simvastatin | 12 | $104 |
| Lisinopril | 19 | $102 |
| Omeprazole | 11 | $95 |
| Tamsulosin Hcl | 11 | $84 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 16 | $63 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Simi Valley
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.